Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 29 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

52%

15 trials in Phase 3/4

Results Transparency

0%

0 of 16 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
9(32.1%)
Phase 1
8(28.6%)
Phase 3
6(21.4%)
Phase 2
5(17.9%)
28Total
Phase 4(9)
Phase 1(8)
Phase 3(6)
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT07418372Phase 1Not Yet Recruiting

Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine

Role: lead

NCT07326878Phase 1Not Yet Recruiting

Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine

Role: lead

NCT07144202Enrolling By Invitation

Study on the Persistence of Immunity Following EV71 Vaccination

Role: lead

NCT06920069Phase 4Not Yet Recruiting

Study of Concomitant Administration of the sIPV and DTaP or MMR

Role: lead

NCT06800950Phase 3Not Yet Recruiting

Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Role: lead

NCT06622590Phase 1Active Not Recruiting

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Role: lead

NCT06460545Phase 4Not Yet Recruiting

Phase IV Study of Concomitant Administration of the sIPV and HepA

Role: lead

NCT06209398Phase 4Unknown

Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine

Role: collaborator

NCT06184542Phase 1Recruiting

Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine

Role: lead

NCT06080906Phase 2Unknown

Phase II Clinical Trial of the Inactivated Rotavirus Vaccine

Role: lead

NCT06146088Phase 4Recruiting

Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine

Role: lead

NCT01391494Phase 1Completed

A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants

Role: lead

NCT01512706Phase 2Completed

A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants

Role: lead

NCT01510366Phase 3Completed

The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)

Role: lead

NCT04412538Phase 1Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

Role: lead

NCT04591405Phase 2Unknown

Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11

Role: lead

NCT01551810Phase 3Completed

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Role: lead

NCT04220515Phase 4Completed

Inactivated Poliomyelitis Vaccine Made From Sabin Strain

Role: lead

NCT03614702Phase 3Completed

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

Role: lead

NCT04470609Phase 1Completed

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years

Role: lead